Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats

British Journal of Pharmacology

Volumn 147, Issue 8, 2006, Pages 944-950

  Chang, Kuo Chu ^a   Hsu, Kwan Lih ^b   Tseng, Chuen Den ^b   Lin, Yue Der ^c   Cho, Yi Li ^a   Tseng, Yung Zu ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FENG CHIA UNIVERSITY   (Taiwan)

Author keywords

Advanced glycation endproducts; Aminoguanidine; Aortic input impedance; Pulse wave reflection; Streptozotocin diabetic rats

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; COLLAGEN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTERY WALL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC ANGIOPATHY; HEART LEFT VENTRICLE; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERGLYCEMIA; IMPEDANCE; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PULSE WAVE; RAT; RIGIDITY; STREPTOZOCIN DIABETES; VASCULAR RESISTANCE;

ANIMALS; AORTA; BLOOD PRESSURE; CARDIOMEGALY; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; GUANIDINES; MALE; RATS; RATS, WISTAR;

EID: 33646542339     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706684     Document Type: Article

References (45)

1. BAYNES, J.W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes, 40, 405-412.
2. BAYNES, J.W. & THROPE, S.R. (1999). Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes, 48, 1-9.
3. BROWNLEE, M., CERAMI, A. & VLASSARA, H. (1988). Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 318, 1315-1321.
4. BROWNLEE, M., VLASSARA, H., KOONEY, A., ULRICH, P. & CERAMI, A. (1986). Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science, 232, 1629-1632.
5. BROWNLEE, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820.
6. BUCALA, R. (1997). Lipid and lipoprotein modification by GEA's: role in atherosclerosis. Exp. Physiol., 82, 327-337.
7. CHANG, K.C., CHEN, T.J., PENG, Y.I., LI, T.H. & TSENG, Y.Z. (2000). Impaired vascular dynamics in normotensive diabetic rats induced by streptozotocin: tapered T-tube model analysis. J. Ther. Biol., 204, 371-380.
8. CHANG, K.C., HSU, K.L. & TSENG, Y.Z. (2003). Effects of diabetes and gender on mechanical properties of the arterial system in rats: aortic impedance analysis. Exp. Biol. Med., 228, 70-78.
9. CORMAN, B., DURIEZ, M., POITEVIN, P., HEUDES, D., BRUNEVAL, P., TEDGUI, A. & LÉVY, B.I. (1998). Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A., 95, 1301-1306.
10. CORBETT, J.A., TILTON, R.G., CHANG, K., HASAN, K.S., IDO, Y., WANG, J.L., SWEETLAND, M.A., LANCASTER, J.R., WILLIAMSON, J.R. & MCDANIEL, M.L. (1992). Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes, 41, 552-556.
11. CRIJNS, F.R., STRUIJKER-BOUDIER, H.A. & WOLFFENBUTTEL, B.H. (1998). Arteriolar reactivity in conscious diabetic rats. Influence of aminoguanidine treatment. Diabetes, 47, 918-923.
12. DYER, D.G., DUNN, J.A., THORPE, S.R., BAILLIE, K.E., LYONS, T.J., MCCANCE, D.R. & BAYNES, J.W. (1993). Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest., 91, 2463-2469.
13. EDELSTEIN, D. & BROWNLEE, M. (1992). Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes, 41, 26-29.
14. GABALLA, M.A., RAYA, T.E., HOOVER, C.A. & GOLDMAN, S. (1999). Effects of endothelial and inducible nitric oxide synthases inhibition on circulatory function in rats after myocardial infarction. Cardiovasc. Res., 42, 627-635.
15. GILLERY, P., MONBOISSE, J.C., MAQUART, F.X. & BOREL, J.P. (1989). Dose oxygen free radical increased formation explain long term complications of diabetes mellitus? Med. Hypotheses, 29, 47-50.
16. GUYTON, A.C. (1992). Human Physiology and Mechanisms of Disease. Philadelphia: Saunders, p. 115.
17. HILL, M.A. & EGE, E.A. (1994). Active and passive mechanical properties of isolated arterioles from STZ-induced diabetic rats. Effect of aminoguanidine treatment. Diabetes, 43, 1450-1456.
18. HUIJBERTS, M.S., WOLFFENBUTTEL, B.H., BOUDIER, H.A., CRIJNS, F.R., KRUSEMAN, A.C., POITEVIN, P. & LÉVY, B.I. (1993). Amino-guanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J. Clin. Invest., 92, 1407-1411.
19. KASS, D.A., SHAPIRO, E.P., KAWAGUCHI, M., CAPRIOTTI, A.R., SCUTERI, A., DEGROOF, R.C. & LAKATTA, E.G. (2001). Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation, 104, 1464-1470.
20. LAXMINARAYAN, S., SIPKEMA, P. & WESTERHOF, N. (1978). Characterization of the arterial system in the time domain. IEEE Trans. Biomed. Eng., 25, 177-184.
21. LIU, A., BRIN, K.P. & YIN, F.C.P. (1986). Estimation of total arterial compliance: an improved method and evaluation of current methods. Am. J. Physiol., 251 (Heart Circ. Physiol., 20), H588-H600.
22. MILNOR, W.R. (1989). Hemodynamics. Baltimore: Williams & Wilkins Co.
23. MITCHELL, G.F., PFEFFER, M.A., WESTERHOF, N. & PFEFFER, J.M. (1994). Measurement of aortic input impedance in rats. Am. J. Physiol., 267 (Heart Circ. Physiol., 36), H1907-H1915.
24. NILSSON, B. (1999). Biological effects of aminoguanidine: an update. Inflamm. Res., 48, 509-515.
25. NICHOLS, W.W. & O'ROURKE, M.F. (1998). McDonald's Blood Flow in Arteries. London: Arnold.
26. OBERLEY, L.W. (1988). Free radicals and diabetes. Free Radic. Biol. Med., 5, 113-124.
27. O'ROURKE, M.F., AVOLIO, A.P. & NICHOLS, W.W. (1987). Left ventricular-systemic arterial coupling in humans and strategies to improve coupling in disease states. In: Ventricular/Vascular Coupling. ed. Yin, F.C.P., pp. 1-19. New York: Springer-Verlag.
28. OZYAZGAN, S., UNLUCERCI, Y., BEKPINAR, S. & AKKAN, A.G. (2000). Impaired relaxation in aorta from streptozotocin-diabetic rats: effect of aminoguanidine treatment. Int. J. Exp. Diabet. Res., 1, 145-153.
29. PARVING, H.H. (2001). Diabetic nephropathy: prevention and treatment. Kidney Int., 60, 2041-2055.
30. PIEPER, G.M. (1999). Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia, 42, 204-213.
31. PIEPER, G.M., MOORE-HILTON, G. & ROZA, A.M. (1996). Evaluation of the mechanism of endothelial dysfunction in the genetically-diabetic BB rat. Life Sci., 58, 147-152.
32. SNYDER, T. & BREDT, A. (1992). Biological roles of nitric oxide. Sci. Am., 5, 68-77.
33. SOULIS, T., SASTRA, S., THALLAS, V., MORTENSEN, S.B., WILKEN, M., CLAUSEN, J.T., BJERRUM, O.J., PETERSEN, H., LAU, J., JERUMS, G., BOEL, E. & COOPER, M.E. (1999). A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia, 42, 472-479.
34. STADLER, K., JENEI, V., SOMOGYI, A. & JAKUS, J. (2005). Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats. Diabetes Metab. Res. Rev., 21, 189-196.
35. TESFAMARIAM, B. (1994). Free radicals in diabetic endothelial cell dysfunction. Free Radic. Biol. Med., 16, 383-391.
36. TILTON, R.G., CHANG, K., HASAN, K.S., SMITH, S.R., PETRASH, J.M., MISKO, T.P., MOORE, W.M., CURRIE, M.G., CORBETT, J.A., MCDANIEL, M.L. & WILLIAMSON, J.R. (1993). Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes, 42, 221-232.
37. TOMLINSON, K.C., GARDINER, S.M., HEBDEN, R.A. & BENNETT, T. (1992). Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol. Rev., 44, 103-150.
38. TURK, Z., MIŠUR, I., TURK, N. & BENKO, B. (1999). Rat tissue collagen modified by advanced glycation: correlation with duration of diabetes and glycemic control. Clin. Chem. Lab. Med., 37, 813-820.
39. VLASSARA, H., BUCALA, R. & STRIKER, L. (1994). Pathogenic effects of advanced glycosylation: biochemical, biological, and clinical implications for diabetes and aging. Lab. Invest., 70, 138-151.
40. WEST, J.B. (1991). BEST AND TAYLOR'S physiological basis of medical practice. In: Dynamics of the Peripheral Circulation, ed. West, J.B., pp. 147-149. Baltimore: Williams & Wilkins.
41. WESTERHOF, N., SIPKEMAM, P., VANDEN-BOS, G.C. & ELZINGA, G. (1972). Forward and backward waves in the arterial system. Cardiovasc. Res., 6, 648-656.
42. WILLIAMSON, J.R., CHANG, K., TILTON, R.G. & KILO, C. (1989). Models for studying diabetic complications. In: Diabetes Mellitus: Pathophysiology and Therapy. eds. Creutzfeldt W. & Lefebvre P., pp. 142-151. NewYork: Springer-Verlag.
43. WOLFF, S.P. (1993). Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br. Med. Bull., 49, 642-652.
44. WOLFFENBUTTEL, B.H., BOULANGER, C.M., CRIJNS, F.R., HUIJBERTS, M.S., POITEVIN, P., SWENNEN, G.N., VASAN, S., EGAN, J.J., ULRICH, P., CERAMI, A. & LÉVY, B.I. (1988). Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. U.S.A., 95, 4630-4634.
45. ZATZ, R. & BRENNER, B.M. (1986). Pathogenesis of diabetic microangiopathy: the hemodynamic view. Am. J. Med., 80, 443-453.